Biotech firm advances skin cancer treatment program

Tampa-based Morphogenesis Inc.’s vaccine will be tested on humans in a clinical trial.

  • By Business Observer Staff
  • | 1:47 p.m. August 27, 2018
  • | 0 Free Articles Remaining!
Investor Kiran Patel speaks at an event held to celebrate Morphogenesis Inc.'s successful application to conduct human clinical trials of its skin cancer vaccine. Courtesy photo.
Investor Kiran Patel speaks at an event held to celebrate Morphogenesis Inc.'s successful application to conduct human clinical trials of its skin cancer vaccine. Courtesy photo.
  • Tampa Bay-Lakeland
  • Share

TAMPA —  Morphogenesis Inc., a Tampa-based biotech company that raised $16 million in investment funding in May, will embark on the first human clinical study of its immunotherapeutic vaccine designed to treat melanoma.

According to a press release, the U.S. Food & Drug Administration has approved the tests, which are the product of a collaboration between Morphogenesis and the cutaneous oncology program at Tampa’s Moffitt Cancer Center.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • December 18, 2025
Kolter, Casto buy 19 acres in Parrish
  • December 18, 2025
Tampa Museum of Art director to retire
  • December 18, 2025
ESPN report: Naples' Hoffmann family buying NHL hockey team
  • December 18, 2025
4-acre entertainment district to be built in downtown Tampa

Sponsored Content